Carisma Therapeutics Inc. (CARM) - Total Assets
Based on the latest financial reports, Carisma Therapeutics Inc. (CARM) holds total assets worth $6.55 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CARM operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Carisma Therapeutics Inc. - Total Assets Trend (2011–2024)
This chart illustrates how Carisma Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See CARM net asset value for net asset value and shareholders' equity analysis.
Carisma Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Carisma Therapeutics Inc.'s total assets of $6.55 Million consist of 78.2% current assets and 21.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.8% |
| Accounts Receivable | $2.86 Million | 9.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Carisma Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Carisma Therapeutics Inc. stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Carisma Therapeutics Inc.'s current assets represent 78.2% of total assets in 2024, an increase from 37.1% in 2011.
- Cash Position: Cash and equivalents constituted 58.8% of total assets in 2024, up from 26.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 9.4% of total assets.
Carisma Therapeutics Inc. Competitors by Total Assets
Key competitors of Carisma Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Carisma Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 3.23 | 3.48 |
| Quick Ratio | 0.86 | 3.23 | 3.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-942.00K | $23.58 Million | $44.82 Million |
Carisma Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Carisma Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 114.10 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -66.0% |
| Total Assets | $30.46 Million |
| Market Capitalization | $8.37K USD |
Valuation Analysis
Below Book Valuation: The market values Carisma Therapeutics Inc.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Carisma Therapeutics Inc.'s assets decreased by 66.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Carisma Therapeutics Inc. (2011–2024)
The table below shows the annual total assets of Carisma Therapeutics Inc. from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $30.46 Million | -65.99% |
| 2023-12-31 | $89.55 Million | +24.12% |
| 2022-12-31 | $72.15 Million | -76.92% |
| 2021-12-31 | $312.60 Million | +65.87% |
| 2020-12-31 | $188.45 Million | +64.78% |
| 2019-12-31 | $114.36 Million | +2.51% |
| 2018-12-31 | $111.56 Million | +48.56% |
| 2017-12-31 | $75.10 Million | -27.86% |
| 2016-12-31 | $104.10 Million | +182.68% |
| 2015-12-31 | $36.83 Million | -33.05% |
| 2014-12-31 | $55.00 Million | +389.45% |
| 2013-12-31 | $11.24 Million | +18.25% |
| 2012-12-31 | $9.50 Million | +256.59% |
| 2011-12-31 | $2.67 Million | -- |
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more